Latest News
China's new recombinant COVID-19 vaccine starts human tests
Last Updated: 2021-04-25 12:31 | Xinhua
 Save  Print   E-mail
Sinopharm, the Chinese pharmaceutical giant, has commenced phase-1 and phase-2 clinical trials for its new recombinant vaccine against COVID-19 in central China's Henan Province since Saturday.
Developed by the China National Biotec Group (CNBG), a Sinopharm's bioscience subsidiary, the vaccine was issued with a clinical research permit from the National Medical Products Administration on April 9.
This is the CNBG's third COVID-19 vaccine candidate approved for human trials.
Researchers started the early-staged clinical trials in the city of Shangqiu, Henan Province. The trials were randomized, double-blind and placebo-controlled, according to a company statement. 

(Editor:Wang Su)

Share to 
Related Articles:
  • Sports
  • Soccer
  • Basketball
  • Tennis
  • Formula One
  • Athletics
  • Others
  • Entertainment
  • Celebrity
  • Movie & TV
  • Music
  • Theater & Arts
  • Fashion
  • Beauty Pageant
About | About the Economic Daily | Contact us
Copyright 2003-2020 China Economic Net. All right reserved
China's new recombinant COVID-19 vaccine starts human tests
Source:Xinhua | 2021-04-25 12:31
Share to